<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>FcRn-targeted immunotherapies represent a promising market opportunity due to their potential to address significant unmet medical needs in autoimmune diseases. Successful FcRn-blocking antibodies are already generating substantial sales, underscoring the target's commercial viability and clinical validation.Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6179389/pipeline-fcrn-targeted-therapies?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=99wx4b&amp;utm_campaign=2252497+-+FcRn-Targeted+Therapies+Pipeline+Competitor+Analysis+Report+2026%3a+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Therapies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Pipeline of FcRn-Targeted Therapies">"Pipeline of FcRn-Targeted Therapies"</a> report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about FcRn-Targeted Immunotherapies provides an up-to-date competitor evaluation in the field of product candidates in research and development targeting FcRn. This report will be prepared on demand within one working day upon order placement. The report lists active FcRn-targeted R&amp;D programs by R&amp;D phase in a tabular format and describes in brief the profile of FcRn-targeted therapies by drug modality. The neonatal Fc receptor ((FcRn) is a protein and Fc receptor found in several types of tissues and cells in the body. It plays a role at two different phases during life: in early development, FcRn is responsible for passing immunity from mother to child; during lifetime, FcRn helps maintain the number of antibodies present in the circulation. FcRn recycles IgGs which have binding sites that fit with FcRn receptors, allowing them to avoid degradation. When an IgG antibody connects to an FcRn receptor, it gets recycled back into the bloodstream and stays in circulation. Unfortunately, the IgG recycling functionality of FcRn may also play a major role in many autoimmune diseases. Severe autoimmune diseases can be associated with high levels of pathogenic immunoglobulin G, or IgG, antibodies for which few innovative biologic treatments have been approved and severe unmet medical need exists. A number of monoclonal antibodies have been created to block the interaction of FcRn and IgG, accelerating the catabolism of antibodies and reducing the concentration of pathogenic IgG autoantibodies. Such treatments have potential in many large and orphan indications, such as multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus, myasthenia gravis and pemphigus vulgaris. At present, three FcRn blocking antibodies have reached the commercial stage. Two of them (Vyvgart and Rystiggo) posted combined 2024 global sales of US$ 2.5 bln making FcRn a commercially attractive and clinically validated target for treatment of antibody-mediated autoimmune diseases. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6179389/pipeline-fcrn-targeted-therapies?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=99wx4b&amp;utm_campaign=2252497+-+FcRn-Targeted+Therapies+Pipeline+Competitor+Analysis+Report+2026%3a+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Therapies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/qq1c6b</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YzBjNmNmM2ItNTMzYi00ODVhLWFlOTEtMDQ1YzhiODk3MDU5LTEwMjY3MzctMjAyNi0wNS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

FcRn-Targeted Therapies Pipeline Competitor Analysis Report 2026: R&D Programs by R&D Phase and Profile of Therapies by Drug Modality

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn